Net financial benefits of digital endpoints publication in Clinical and Translational Science
Date/Time
October 16, 2024
Discussion Topic
Digital measures offer the clinical trials community unparalleled insights into people’s real-life experiences, enhancing our understanding of numerous conditions. So, why haven’t we implemented digital endpoints on a larger scale?
Findings from research conducted by DiMe, Tufts Center for the Study of Drug Development, Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda, and MindMed, now published in the Journal of Clinical & Translational Science, showcase evidence of significant cost reductions and financial benefits tied to leveraging digital endpoints in trials.
